Central venous catheter-related blood stream infections in patients receiving intravenous iloprost for pulmonary hypertension

被引:19
作者
Sammut, D. [1 ,2 ]
Elliot, C. A. [1 ]
Kiely, D. G. [1 ]
Armstrong, I. J. [1 ]
Martin, L. [1 ]
Wilkinson, J. [1 ]
Sephton, P. [1 ]
Jones, J. [1 ]
Hamilton, N. [1 ]
Hurdman, J. [1 ]
McLellan, E. [3 ]
Sabroe, I. [1 ,2 ]
Condliffe, R. [1 ]
机构
[1] Royal Hallamshire Hosp, Pulm Vasc Dis Unit, Sheffield S10 2JF, S Yorkshire, England
[2] Univ Sheffield, Sch Med, Dept Infect & Immun, Acad Unit Resp Med, Sheffield, S Yorkshire, England
[3] Sheffield Teaching Hosp NHS Fdn Trust, Dept Microbiol, Sheffield, S Yorkshire, England
关键词
ARTERIAL-HYPERTENSION; CONTINUOUS-INFUSION; PROSTANOID THERAPY; TREPROSTINIL; EPOPROSTENOL; PROSTACYCLIN; PREVENTION; DILUENT;
D O I
10.1007/s10096-013-1822-z
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Catheter-related blood stream infection (CR-BSI) in patients with pulmonary hypertension (PH) receiving intravenous iloprost via an indwelling central line has previously not been fully described. Recent studies have suggested a link between the pH of prostanoid infusions and the rate and nature of CR-BSI. We have investigated CR-BSI in patients receiving intravenous iloprost at our unit. Databases and hospital records were interrogated for all patients receiving intravenous iloprost between September 2007 and June 2012. Fifty-nine patients received intravenous iloprost via an indwelling central catheter with a total of 23,072 treatment days. There were 15 episodes of CR-BSI, identified using a systematic screening protocol, involving 11 patients giving an overall CR-BSI rate of 0.65/1,000 treatment days. CR-BSI rate for Gram-positive organisms was 0.26/1,000 treatment-days and for Gram-negative organisms was 0.39/1,000 treatment-days. The pH of iloprost in typical dosing regimens was comparable to the pH used in standard-diluent treprostinil and dissimilar to alkaline epoprostenol infusions. The proportion of Gram-negative CR-BSI was similar to that reported for standard-diluent treprostinil. CRP was normal on admission in 33 % of cases of confirmed CR-BSI and remained normal in 13 % of cases. CR-BSI rates with intravenous iloprost are comparable to those observed for other prostanoids. The high proportion of Gram-negative organisms observed and the neutral pH of iloprost infusions support the previously hypothesised link between pH and antimicrobial activity. Although usually elevated during a CR-BSI, CRP may be normal in early infection and a normal result cannot completely exclude infection.
引用
收藏
页码:883 / 889
页数:7
相关论文
共 20 条
  • [1] Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension
    Akagi, Satoshi
    Matsubara, Hiromi
    Ogawa, Aiko
    Kawai, Yusuke
    Hisamatsu, Kenichi
    Miyaji, Katsumasa
    Munemasa, Mitsuru
    Fujimoto, Yoshihisa
    Kusano, Kengo Fukushima
    Ohe, Tohru
    [J]. CIRCULATION JOURNAL, 2007, 71 (04) : 559 - 564
  • [2] Amsha K, 2002, EUR RESP SOC ANN C S
  • [3] Barst R., 2007, Morbidity and Mortality Weekly Report, V56, P170
  • [4] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
    Barst, RJ
    Rubin, LJ
    Long, WA
    McGoon, MD
    Rich, S
    Badesch, DB
    Groves, BM
    Tapson, VF
    Bourge, RC
    Brundage, BH
    Koerner, SK
    Langleben, D
    Keller, CA
    Murali, S
    Uretsky, BF
    Clayton, LM
    Jobsis, MM
    Blackburn, SD
    Shortino, D
    Crow, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) : 296 - 301
  • [5] Certificate of Analysis of Ilomedin, 2008, BAYER HEALTHC BAS HP
  • [6] Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension
    Doran, A. K.
    Ivy, D. D.
    Barst, R. J.
    Hill, N.
    Murali, S.
    Benza, R. L.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 : 5 - 9
  • [7] GlaxoSmithKline, 2008, GLOL PACK INS
  • [8] Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension
    Gomberg-Maitland, M
    Tapson, VF
    Benza, RL
    McLaughlin, VV
    Krichman, A
    Widlitz, AC
    Barst, RJ
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (12) : 1586 - 1589
  • [9] Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost
    Higenbottam, TW
    Butt, AY
    Dinh-Xaun, AT
    Takao, M
    Cremona, G
    Akamine, S
    [J]. HEART, 1998, 79 (02) : 175 - 179
  • [10] Closed-Hub Systems with Protected Connections and the Reduction of Risk of Catheter-Related Bloodstream Infection in Pediatric Patients Receiving Intravenous Prostanoid Therapy for Pulmonary Hypertension
    Ivy, D. Dunbar
    Calderbank, Michelle
    Wagner, Brandie D.
    Dolan, Susan
    Nyquist, Ann-Christine
    Wade, Michael
    Nickels, William M.
    Doran, Aimee K.
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2009, 30 (09) : 823 - 829